Alkem Labs Q2 & H1 FY26 Earnings Conference Call Transcript
Alkem Labs' Q2 & H1 FY26 earnings call transcript reveals strong revenue growth, particularly in India and the U.S. Management anticipates continued market outperformance and margin improvements despite new investments and GST impacts.
The strong financial results, strategic initiatives, and positive outlook suggest a high potential impact on the company's performance and investor confidence.
The announcement highlights strong financial performance, revenue growth across multiple markets, and positive future guidance, indicating a positive outlook for the company.
* Alkem Laboratories Limited hosted an earnings conference call on November 13, 2025, to discuss the Q2 & H1 FY26 results. * Total revenue from operations reached ₹4,001 crore, a YoY growth of 17.2%. * India sales were ₹2,766 crore, with a YoY growth of 12.4%. * U.S. sales stood at ₹764.9 crore, reflecting a YoY growth of 28%. * Non-U.S. sales amounted to ₹424.1 crore, with a YoY growth of 32.4%. * EBITDA grew by 22.3% YoY to ₹920.8 crore, resulting in an EBITDA margin of 23%. * Net profit after minority interest was ₹765.1 crore, a YoY growth of 11.1%. * R&D expenses were ₹130.2 crore, which is 3.3% of the total revenue. * Alkem became the number one company in the Acute segment in the domestic market, according to IQVIA SSA data for Q2 FY26. * Management expects to outperform the market by 100 to 150 basis points and anticipates a double-digit growth, assuming the market grows at around 8% to 8.5%. * The U.S. CDMO plant is now operational, with an expected operational expenditure of ₹50 crore to ₹60 crore per quarter in H2 FY26. * The company expects an EBITDA margin between 19.5% to 20% for the full year. * There is an expected impact of ₹50 crore to ₹60 crore in H2 FY26 due to GST changes affecting the Sikkim facility. * Medtech revenue was approximately ₹2.5 crore with 900 knee replacements, while Adroit maintained a run rate of around ₹15 crore for the quarter. * Enzene U.S. operations revenue averages around ₹15 crore to ₹20 crore per quarter and is expected to close between ₹70 crore to ₹80 crore from Enzene CDMO U.S. business. * R&D expenses are expected to be within 4% to 5% of revenue.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.